Abstract
Purpose: We examined the biodistribution and pharmacokinetics of 111In-labeled rGel/BLyS, a gelonin toxin (rGel)-B lymphocyte stimulator (BLyS) fusion protein. Materials and Methods: rGel/BLyS was labeled with In-111 through DTPA with a labeling efficiency >95%. Biodistribution/imaging studies were obtained in severe-combined immunodeficiency mice bearing diffuse large B cell lymphoma OCI-Ly10. Pharmacokinetic studies were performed in BALB/c mice. Results: In vitro, DTPA-conjugated rGel/BLyS displayed selective cytotoxicity against OCI-Ly10 cells and mantle cell lymphoma JeKo cells. In vivo, rGel/BLyS exhibited a tri-exponential disposition with a rapid initial mean distribution followed by an extensive mean distribution and a long terminal elimination phase. At 48 h after injection, uptake of the radiotracer in tumors was 1.25%ID/g, with a tumor-to-blood ratio of 13. Tumors were clearly visualized at 24-72 h postinjection. Micro-SPECT-CT images and ex vivo analyses confirmed the accumulation of rGel/BLyS in OCI-Ly10 tumors. Conclusions: 111In- DTPA-rGel/BLyS are distributed to B cell tumors and induce apoptosis in tumors. Preclinical antitumor studies using rGel/BLyS should use a twice-per-week treatment schedule.
Original language | English (US) |
---|---|
Pages (from-to) | 721-729 |
Number of pages | 9 |
Journal | Molecular Imaging and Biology |
Volume | 13 |
Issue number | 4 |
DOIs | |
State | Published - Aug 2011 |
Keywords
- B cell lymphoma
- Biodistribution
- Cytokine blymphocyte stimulator
- Gamma imaging
- Gelonin
- Pharmacokinetics
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research